Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Bioorthogonal Prodrug Activation at Nanomolar Levels

Objectif

Bioorthogonal click-to-release chemistry enables selective bond cleavage in complex biological environments and has emerged as a powerful concept for controlled prodrug activation, most prominently through trans-cyclooctenes and tetrazines. However, established systems face trade-offs between reaction speed, release efficiency, and stability, limiting their application in therapeutic settings. We have discovered a strained cleavable trans-cyclooctene linker that uniquely combines ultrafast click kinetics with high release efficiency and stability. Compared to current approaches, this TCO exhibits more than 20-fold faster click reactivity, enabling activation under conditions not accessible with existing methods. This advance enables efficient prodrug activation even at nanomolar concentrations, opening new possibilities for targeted therapeutic strategies that remain out of reach. The project will establish proof of concept by developing TCO-caged prodrugs of clinically relevant therapeutics and validating this process using tetrazine triggers, including scaffolds already advanced to clinical trials. Release kinetics, stability in biological media, and biological activity will be systematically evaluated in solution and cellular models. A central concept of the project is click accumulation, where ultrafast kinetics enable local capture and activation of circulating prodrugs. This will be demonstrated in microfluidic models that mimic vascular flow, providing evidence for efficient activation and therapeutic efficacy at low systemic concentrations. Supported by an initial patent filing, this technology represents a versatile platform with strong translational potential. It is expected to create new opportunities for safer and more effective targeted therapeutics, with potential applications in prodrug strategies and related delivery systems.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

TECHNISCHE UNIVERSITAET WIEN
Contribution nette de l'UE
€ 150 000,00
Coût total
Aucune donnée

Bénéficiaires (1)